Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-03-14

FDA Approved: AVYCAZ — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approved a supplemental application for AVYCAZ (ceftazidime-avibactam) that updates labeling in connection with the supplement.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Avycaz (ceftazidime-avibactam)

Snippet

SUPPL AP for AVYCAZ (CEFTAZIDIME, AVIBACTAM)